Gainers

• Soligenix (NASDAQ:SNGX) shares rose 30.4% to $0.67 during Tuesday's after-market session. The company's market cap stands at $5.7 million.
• CareCloud (NASDAQ:CCLD) stock increased by 6.78% to $2.36. The market value of their outstanding shares is at $96.8 million.
• GlucoTrack (NASDAQ:GCTK) stock rose 5.76% to $0.63. The company's market cap stands at $3.1 million.
• MetaVia (NASDAQ:MTVA) shares increased by 5.72% to $3.14. The market value of their outstanding shares is at $19.8 million.
• Dermata Therapeutics (NASDAQ:DRMA) shares rose 5.54% to $1.3. The market value of their outstanding shares is at $5.0 million.
• Mereo BioPharma Group (NASDAQ:MREO) shares moved upwards by 5.12% to $0.35. The market value of their outstanding shares is at $44.4 million.

Losers

• Artelo Biosciences (NASDAQ:ARTL) shares fell 21.1% to $1.35 during Tuesday's after-market session. The market value of their outstanding shares is at $2.7 million.
• Akari Therapeutics (NASDAQ:AKTX) shares decreased by 9.38% to $16.14. The market value of their outstanding shares is at $20.9 million.
• Beyond Air (NASDAQ:XAIR) stock fell 8.58% to $0.4. The market value of their outstanding shares is at $4.2 million.
• Insulet (NASDAQ:PODD) shares decreased by 8.33% to $141.0. The market value of their outstanding shares is at $10.9 billion.
• BiomX (AMEX:PHGE) shares decreased by 7.41% to $1.5. The company's market cap stands at $8.2 million. The company's, Q1 earnings came out 4 days ago.
• Cardio Diagnostics Hldgs (NASDAQ:CDIO) stock declined by 6.78% to $1.65. The company's market cap stands at $4.7 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.